ZimVie (NASDAQ:ZIMV) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• ZimVie (NASDAQ:ZIMV) has received a reaffirmed "Sell (D-)" rating from Weiss Ratings, indicating a negative outlook for the stock.
• The company reported earnings that surpassed analysts' expectations, with an EPS of $0.26 against a consensus of $0.21, along with revenue of $116.66 million, outperforming estimates of $112.60 million.
• Institutional investors have shown significant activity in ZimVie, with several large firms increasing their stakes dramatically, suggesting rising interest in the company despite its challenges.

ZimVie (NASDAQ:ZIMV - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other equities analysts also recently commented on ZIMV. B. Riley downgraded shares of ZimVie from a "buy" rating to a "neutral" rating and set a $19.00 target price on the stock. in a research note on Thursday, July 31st. Barclays raised shares of ZimVie from an "underweight" rating to an "equal weight" rating and boosted their price target for the company from $9.00 to $19.00 in a research note on Tuesday, July 22nd. Finally, Wall Street Zen downgraded shares of ZimVie from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, ZimVie currently has a consensus rating of "Reduce" and a consensus target price of $17.75.

ZimVie Trading Up 0.1%

ZIMV stock traded up $0.02 during trading on Wednesday, reaching $18.94. 69,218 shares of the stock were exchanged, compared to its average volume of 326,098. The company has a current ratio of 2.37, a quick ratio of 1.60 and a debt-to-equity ratio of 0.56. The business has a 50 day moving average price of $18.89 and a 200-day moving average price of $13.09. ZimVie has a 1 year low of $8.15 and a 1 year high of $19.01. The firm has a market capitalization of $534.16 million, a price-to-earnings ratio of -27.05 and a beta of 2.17.

ZimVie (NASDAQ:ZIMV - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.05. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. The company had revenue of $116.66 million for the quarter, compared to the consensus estimate of $112.60 million. On average, research analysts predict that ZimVie will post 0.6 earnings per share for the current year.

Institutional Investors Weigh In On ZimVie

Several large investors have recently added to or reduced their stakes in ZIMV. AlphaQuest LLC grew its holdings in ZimVie by 2,695.9% during the 1st quarter. AlphaQuest LLC now owns 8,947 shares of the company's stock worth $97,000 after acquiring an additional 8,627 shares in the last quarter. Quantbot Technologies LP purchased a new position in ZimVie during the 1st quarter worth $98,000. Sei Investments Co. purchased a new position in ZimVie during the 2nd quarter worth $94,000. Brevan Howard Capital Management LP purchased a new position in shares of ZimVie in the 2nd quarter valued at about $102,000. Finally, Jones Financial Companies Lllp grew its stake in ZimVie by 9,039.1% in the 1st quarter. Jones Financial Companies Lllp now owns 12,612 shares of the company's stock valued at $136,000 after acquiring an additional 12,474 shares during the last quarter. 95.63% of the stock is owned by hedge funds and other institutional investors.

About ZimVie

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.